Medicina clinica
The most recent articles from:
December 2024
-
Observational Study
Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab.
To analyze the prevalence of hyperparathyroidism in patients treated with zoledronic acid (ZA) or denosumab, its relationship with other parameters and how it affects on bone mineral density (BMD) evolution. ⋯ A high incidence of hyperparathyroidism was observed in patients treated with AZ and especially denosumab. Hyperparathyroidism correlated inversely with glomerular filtration rate and albumin-corrected calcium. Elevated PTH does not appear to affect short-term bone mineral density evolution.